HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Aquestive Therapeutics, Inc.

Contributing Author

Recent Articles by Aquestive Therapeutics, Inc.

Mar-30
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm (dibutepinephrine) Sublingual Film AQST GlobeNewswire
Mar-20
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer AQST GlobeNewswire
Mar-09
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) AQST GlobeNewswire
Mar-04
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update AQST +6.07% GlobeNewswire
Feb-25
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences AQST GlobeNewswire
Feb-24
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET AQST GlobeNewswire
Feb-23
Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference AQST GlobeNewswire
Feb-20
Aquestive Therapeutics to Present New Clinical Data on Anaphylm (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting AQST GlobeNewswire
Feb-18
Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer AQST GlobeNewswire
Feb-02
Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm AQST +38.98% GlobeNewswire
Jan-09
Aquestive Therapeutics Announces Regulatory Development for Anaphylm (dibutepinephrine) Sublingual Film and Provides Business Update AQST -37.04% GlobeNewswire
Nov-24
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference AQST GlobeNewswire
Nov-05
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update AQST GlobeNewswire
Nov-04
Aquestive Therapeutics Announces Leadership Expansion to Support Growth AQST -6.32% GlobeNewswire
Nov-03
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler AQST GlobeNewswire
Oct-30
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting AQST GlobeNewswire
Oct-27
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET AQST GlobeNewswire
Oct-08
Aquestive Therapeutics Broadens Patent Estate for Anaphylm AQST GlobeNewswire
Sep-04
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm AQST +28.10% GlobeNewswire
Aug-26
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences AQST GlobeNewswire
Aug-14
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock AQST GlobeNewswire
Aug-14
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm (epinephrine) Sublingual Film AQST GlobeNewswire
Aug-11
Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update AQST GlobeNewswire
Aug-04
Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET AQST +5.24% GlobeNewswire
Jul-22
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer AQST -6.15% GlobeNewswire
Jul-15
Aquestive Therapeutics Provides International Expansion Update for Anaphylm (epinephrine) Sublingual Film AQST GlobeNewswire
Jul-07
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism AQST GlobeNewswire
Jun-25
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit AQST GlobeNewswire
Jun-16
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm for the Treatment of Severe Allergic Reactions AQST GlobeNewswire
May-12
Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update AQST -19.65% AQST GlobeNewswire
May-05
Aquestive Therapeutics to Participate in Citizens Life Sciences Conference AQST -5.67% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)